ULBI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ULBI is not a good buy right now. With no Intellectia buy signals, weakening momentum (negative/expanding MACD histogram), and pattern-based downside odds (80% probability of -1.5% next day; -3.67% next week), the current setup favors avoiding/stepping aside rather than entering immediately—especially for an impatient buyer who won’t wait for a cleaner entry.
Trend/Momentum: Momentum is slightly bearish—MACD histogram is -0.0106 (below zero) and negatively expanding, which typically signals fading upside and increasing downside pressure. RSI(6)=50.925 is neutral (no oversold bounce signal). Moving averages are converging, implying a lack of strong directional trend but with momentum tilting negative. Key levels: Pivot=6.533; price is around 6.38 regular-session and ~6.50 post-market, i.e., near the pivot but not decisively above it. Support levels: S1=6.098 then S2=5.829. Resistance: R1=6.969 then R2=7.238. With resistance overhead and MACD weakening, odds favor a retest of support before a sustainable breakout. Pattern/Stats: Similar candlestick-pattern analysis suggests a bearish near-term bias (next day/week/month expected drift lower).
Intellectia Proprietary Trading Signals
Earnings catalyst ahead: Next earnings on 2026-02-17 (pre-market) can reset expectations if profitability/margins recover.
Revenue is growing strongly (Q3 2025 +21.51% YoY), which can support a turnaround narrative if costs stabilize.
Post-market uptick (+2.69% to ~6.
suggests some dip-buying interest, though not confirmed by broader signals.
Profitability deterioration: Q3 2025 net income turned to a larger loss and EPS fell to -0.07, undermining confidence in near-term fundamentals.
Margin compression: Gross margin down to 22.18% (down 8.80% YoY) suggests cost pressure and/or unfavorable mix.
Technical momentum is weakening (MACD negative and expanding) with no proprietary buy signals.
No supportive news flow in the last week; no evident near-term positive catalyst before earnings.
Stat/pattern model points to continued downside bias over the next day/week/month.
Latest quarter: 2025/Q3. Revenue rose to $43.371M (+21.51% YoY), but profitability worsened: Net Income was -$1.22M (down -572.87% YoY), EPS -0.07 (down -450% YoY). Gross margin declined to 22.18% (down 8.80% YoY). Overall: strong top-line growth but weakening margins and losses—growth quality is currently poor.
No analyst rating/price-target change data was provided, so there’s no observable recent trend in upgrades/downgrades or target revisions to lean on. Wall Street pro/con view cannot be validated from the dataset. (Separately: hedge funds and insiders are reported Neutral with no significant recent trading trends; congress trading data shows no recent activity in the last 90 days.)
